. 2015 Feb 11;59(3):1569–1582. doi: 10.1128/AAC.04623-14

TABLE 3.

VX-787-selected PB2 variant viruses maintain susceptibility to neuraminidase inhibitors in vitro

Influenza virus variant	VX-787 EC₅₀ (μM), no. of expts^a	Fold shift			Frequency of variant in human data set
Influenza virus variant	VX-787 EC₅₀ (μM), no. of expts^a	VX-787 EC₅₀^b	Oseltamivir carboxylate IC₅₀^c	Zanamivir IC₅₀^c	Frequency of variant in human data set
WT	0.0030 ± 0.0018, n = 18	1.0	1.0	1.0
PB2-Q306H	0.56 ± 0.71, n = 9	186	<2	<2	0/8,919
PB2-S324I	0.47 ± 0.071, n = 3	157	<2	<2	0/8,942
PB2-S324N	0.38 ± 0.68, n = 5	127	<2	<2	1/8,942
PB2-S324R	0.19 ± 0.23, n = 12	63	<2	<2	0/8,942
PB2-F404Y	0.77 ± 0.50, n = 8	257	<2	<2	3/8,912
PB2-N510T	0.40 ± 0.050, n = 3	133	<2	<2	1/8,926

Data shown represent means ± standard deviations of the results of n independent experiments.

EC₅₀ determined using 3-day CPE assay.

IC₅₀ determined using enzymatic neuraminidase assay.